Given the imminent publication by NICE of their draft appraisal document for dasatinib, nilotinib and imatinib in 1st line use, I thought it  a good idea to update you all on CMLSg's campaigning activities during the latter half of this year.

 University of Pennsylvania (Penn State) researchers Sandeep Prahbu and Rober Paulson with interest in Leukaemia studied a compound called D12-PGJ3 derived from fish oil which targeted and killed CML stem cells in mice. It is hoped that this might lead to a cure for the disease as the CML stem cell remains active in most patients despite successful therapy with TK inhibitors.

Subcutaneous Omacetaxine Effective in Chronic- or Accelerated-Phase CML Resistant to 2 or More TKIs Including Imatinib

Posting Date: December 19, 2011

Post hoc analysis of 2 open-label, multicenter, single-arm, phase II studies

http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202011/Tracks/CML/Capsules/3761.aspx

Bosutinib Active in Patients With Philadelphia Chromosome–Positive Leukemia Resistant to Second-Generation TKIs

Posting Date: December 13, 2011

Nonrandomized, multicenter, open-label, phase I/II trial

Summary of Key Conclusions

• Bosutinib active in patients with Philadelphia chromosome–positive (Ph+) leukemia and with resistance or intolerance to second-generation tyrosine kinase inhibitors (TKIs)
• Activity noted across baseline Bcr-Abl kinase domain mutations conferring clinical resistance to dasatinib (F317L) and nilotinib (Y253H, E255K/V, and F359C/V)
• Limited activity in the presence of T315I mutation, which confers resistance to all TKIs Similar response to bosutinib across patients with chronic-phase chronic myeloid leukemia (CP CML), regardless of baseline resistance mutations
• Baseline mutations associated with diminished response to bosutinib in patients with advanced leukemia
• At completion of bosutinib treatment, new mutations identified in 27% of patients
• Most common emergent mutations: T315I and V299L
• Emergent mutations more common in patients with preexisting mutations
• Patients with emergent mutations more likely to discontinue treatment due to PD or unsatisfactory response to bosutinib

http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202011/Tracks/CML/Capsules/110.aspx

Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia

Elsevier Global Medical News. 2011 Jun 30, S Freeman

• Read more about Durable complete molecular remission of CML following dasatinib cessation, despite adverse disease features
• Email this page